| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024818 |
| Receipt No. | R000028566 |
| Scientific Title | The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosis |
| Date of disclosure of the study information | 2016/11/14 |
| Last modified on | 2020/05/10 (Ver. 8) |
| Basic information | ||
| Public title | The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosis | |
| Acronym | The efficacy and safety of BTX-B on digital ulcers in patients with SSc | |
| Scientific Title | The efficacy and safety of botulinum toxin type B on digital ulcers in patients with systemic sclerosis | |
| Scientific Title:Acronym | The efficacy and safety of BTX-B on digital ulcers in patients with SSc | |
| Region |
|
|
| Condition | |||
| Condition | digital ulcers in systemic sclerosis patients | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To assess the efficacy and safety of BTX-B on digital ulcers in Japanese patients with SSc. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The rate of the patients which digital ulcer was healed by BTX-B at 8 weeks after treatment compared with that treated with placebo control. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | placebo subcutaneously injection into hands with digital ulcers | |
| Interventions/Control_2 | botulinum toxin type B subcutaneously injection into hands with digital ulcers | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | All patients fulfilled the criteria of SSc proposed by the American College of Rheumatology and the American College of Rheumatology/European League Against Rheumatism classification criteria.
SSc patients with digital ulcers |
|||
| Key exclusion criteria | Patients under the age 18, with the pregnancy or having the past medical histories with BTX were excluded. | |||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Gunma University Graduate School of Medicine | ||||||
| Division name | Department of Dermatology | ||||||
| Zip code | 371-8511 | ||||||
| Address | 3-39-22 Showa, Maebashi, Gunma 371-8511. | ||||||
| TEL | 027-220-8284 | ||||||
| smotegi@gunma-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Gunma University Graduate School of Medicine | ||||||
| Division name | Department of Dermatology | ||||||
| Zip code | 371-8511 | ||||||
| Address | 3-39-22 Showa, Maebashi, Gunma 371-8511. | ||||||
| TEL | 027-220-8284 | ||||||
| Homepage URL | |||||||
| gunmaciru-office@umin.ac.jp | |||||||
| Sponsor | |
| Institute | Gunma University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Ministry of Health, Labour
and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Gunma University |
| Address | Gunma |
| Tel | 027-220-7111 |
| gunmaciru-office@umin.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 群馬大学医学部附属病院(群馬県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 10 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028566 |